Glucocorticoids do not inhibit antitumor activity of activated CD8 + T cells

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 517-524

  Hinrichs, Christian S ^a   Palmer, Douglas C ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Glucocorticoid; Immunotherapy; T cell

Indexed keywords

CD8 ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID; GLYCOPROTEIN GP 100; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; FEMALE; IN VITRO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR REGRESSION;

EID: 27444444916     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000177999.95831.7b     Document Type: Article

References (51)

1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
2. Franchimont D, Kino T, Galon J, et al. Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation. 2003;10:247-260.
3. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004;101:1969-1974.
4. Palmer DC, Balasubramaniam S, Hanada K, et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173:7209-7216.
5. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-580.
6. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675.
7. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14639-14645.
8. Rosenberg SA, Yang JC, Robbins PF, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003;26:385-393.
9. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
10. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277-286.
11. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309-345.
12. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111-117.
13. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based antitumor immunotherapy. Curr Opin Immunol. 2005;17:195-201.
14. Zhang Y, Louboutin JP, Zhu J, et al. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest. 2002;109:1335-1344.
15. Rea D, van Kooten C, van Meijgaarden KE, et al. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood. 2000;95:3162-3167.
16. Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol. 1999;162:6473-6481.
17. Nelson DJ, McWilliam AS, Haining S, et al. Modulation of airway intraepithelial dendritic cells following exposure to steroids. Am J Respir Crit Care Med. 1995;151:475-481.
18. Chen X, Murakami T, Oppenheim JJ, et al. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol. 2004;34:859-869.
19. Franchimont D, Louis E, Dewe W, et al. Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regul Pept. 1998;73:59-65.
20. Almawi WY, Hess DA, Rieder MJ. Multiplicity of glucocorticoid action in inhibiting allograft rejection. Cell Transplant. 1998;7:511-523.
21. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol. 2002;71:9-15.
22. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002;195:603-616.
23. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci. 2004;1024:124-137.
24. Zukiwski AA, David CL, Coan J, et al. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer. 1990;65:1521-1524.
25. Iwata M, Hanaoka S, Sato K. Rescue of thymocytes and T cell hybridomas from glucocorticoid-induced apoptosis by stimulation via the T cell receptor/CD3 complex: a possible in vitro model for positive selection of the T cell repertoire. Eur J Immunol. 1991;21:643-648.
26. Iwata M, Ohoka Y, Kuwata T, et al. Regulation of T cell apoptosis via T cell receptors and steroid receptors. Stem Cells. 1996;14:632-641.
27. Jamieson CA, Yamamoto KR. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci USA. 2000;97:7319-7324.
28. Riccardi C, Zollo O, Nocentini G, et al. Glucocorticoid hormones in the regulation of cell death. Therapie. 2000;55:165-169.
29. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood. 2001;98:743-753.
30. Ko M, Jang J, Ahn J, et al. T cell receptor signaling inhibits glucocorticoid-induced apoptosis by repressing the SRG3 expression via Ras activation. J Biol Chem. 2004;279:21903-21915.
31. Zacharchuk CM, Mercep M, Chakraborti PK, et al. Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol. 1990;145:4037-4045.
32. Yang Y, Mercep M, Ware CF, et al. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med. 1995;181:1673-1682.
33. Kasibhatla S, Genestier L, Green DR. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem. 1999;274:987-992.
34. Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med. 1995;181:33-40.
35. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest. 1994;93:33-39.
36. Fernandez-Ruiz E, Rebollo A, Nieto MA, et al. IL-2 protects T cell hybrids from the cytolytic effect of glucocorticoids. Synergistic effect of IL-2 and dexamethasone in the induction of high-affinity IL-2 receptors. J Immunol. 1989;143:4146-4151.
37. Nieto MA, Lopez-Rivas A. IL-2 protects T lymphocytes from glucocorticoid-induced DNA fragmentation and cell death. J Immunol. 1989;143:4166-4170.
38. Zubiaga AM, Munoz E, Huber BT. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J Immunol. 1992;149: 107-112.
39. Biola A, Lefebvre P, Perrin-Wolff M, et al. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol. 2001;15:1062-1076.
40. Gurney AL, Marsters SA, Huang RM, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9:215-218.
41. Nocentini G, Giunchi L, Ronchetti S, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA. 1997;94:6216-6221.
42. Kwon B, Yu KY, Ni J, et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem. 1999;274:6056-6061.
43. Liu ZG, Smith SW, McLaughlin KA, et al. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene Nur77. Nature. 1994;367:281-284.
44. Woronicz JD, Calnan B, Ngo V, et al. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature. 1994;367:277-281.
45. Philips A, Maira M, Mullick A, et al. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol. 1997; 17:5952-5959.
46. Franchimont D, Galon J, Vacchio MS, et al. Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol. 2002;168:2212-2218.
47. Bumgardner GL, Gao D, Li J, et al. Rejection responses to allogeneic hepatocytes by reconstituted SCID mice, CD4, KO, and CD8 KO mice. Transplantation. 2000;70:1771-1780.
48. Bumgardner GL, Li J, Prologo JD, et al. Patterns of immune responses evoked by allogeneic hepatocytes: evidence for independent co-dominant roles for CD4+ and CD8+ T-cell responses in acute rejection. Transplantation. 1999;68:555-562.
49. He G, Hart J, Kim OS, et al. The role of CDS and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. Transplantation. 1999;67:131-137.
50. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol. 2004;124:777-786.
51. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990; 75:1024-1030.